Advertisement

European Journal of Nuclear Medicine

, Volume 23, Issue 10, pp 1361–1366 | Cite as

Comparison of uptake of99mTc-MIBI,99mTc-tetrofosmin and99mTc-012 into human breast cancer cell lines

  • Marion de Jong
  • Bert F. Bernard
  • Wout A. P. Breeman
  • Geert Ensing
  • Harry Benjamins
  • Willem H. Bakker
  • Theo J. Visser
  • Eric P. Krenning
Original Article

Abstract

Technetium-99m hexakis-2-methoxyisobutylisonitrile (MIBI),99mTc-tetrofosmin and99mTc-Q12 were all introduced for myocardial imaging but found additional applications as they are taken up by different tumours, enabling imaging of these lesions in patients. The aim of this study was to compare the uptake characteristics of these compounds in vitro in the human adenocarcinoma breast cell lines MCF-7 and ZR-75. It was shown that99mTc-MIBI had the highest cellular uptake (15.9%±0.5% dose/mg protein after 60 min in MCF-7, and 14.2%±0.4% dose/mg protein in ZR-75), followed by99mTc-tetrofosmin (6.8%±0.6% dose/mg protein in MCF-7, and 8.2%±0.2% dose/mg protein in ZR-75) and99mTc-Q12 (3,2%±0. I% dose/mg protein in MCF-7, and 3.5%±0.3% dose/mg protein in ZR-75 cells). For all three compounds tenfold differences in specific activity did not influence total cell-associated radioactivity. Uptake of99mTc-MIBI and99mTc-tetrofosmin was obviously lower at 4° C than at 37° C, whereas99mTc-Q12 uptake showed only slight temperature dependence. When uptake was compared in cells grown to different cell densities (1 mg/ml cellular protein versus 0.3 mg/ml), no differences in uptake were detected when uptake was corrected for the amount of cellular protein present in the dishes. Furthermore, for all compounds it was shown that cellular radioactivity decreased rapidly after washing. Apart from the differences in cellular uptake of the three compounds after 60 min, no differences in residual cellular radioactivity after washing were found between the different compounds when expressed as a percentage of their 60-min uptake, suggesting that the efflux process of the radiolabelled compounds was similar. The differences in cell-associated activity after 60 min were thus presumably caused by differences in uptake. It was concluded that of the Tc-labelled compounds tested,99mTc-MIBI had the highest cellular retention in both human breast tumour cell lines. However, for imaging in vivo not only radioactivity in the target organ is important, but also the ratio of radioactivity in the target versus that in the background. Therefore, further studies in vivo need to be performed to investigate which compound is the optimal imaging agent

Key words

Technetium-99m methoxyisobutylisonitrile Technetium-99m tetrofosmin Technetium-99m Q12 MCF-7 ZR-75 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jones AG, Abrams MG, Davison A, et al. Biological studies of a new class of technetium complexes: the hexakis (alkylisonitrile) technetium (II) cations.Int J Nucl Med Biol 1984; 11: 225–234.PubMedGoogle Scholar
  2. 2.
    Eackers FJ, Berman DJ, Maddahi J, et al. Technetium 99m hexakis 2 methoxyisobutyl isonitrile: human distribution, dosimetry, safety, and preliminary comparison to thallium 201 for myocardial perfusion imaging.J Nucl Med 1989; 30: 301–311.PubMedGoogle Scholar
  3. 3.
    Müller S, Guth-tougelides B, Creutzig H. Imaging of malignant tumours with Tc-99m-MIBI [abstract].J Nucl Med 1987; 28: 562.Google Scholar
  4. 4.
    Müller S, Reiners C, Paas M, Guth-tougelidis B, Budach V, Konietzko N, Alberti W. Tc-99m-MIBI and Tl-2-1 uptake in bronchial carcinoma [abstract].Eur J Nucl Med 1989; 30: 485.Google Scholar
  5. 5.
    Nyman R, Rehn S, Glimelius B, Hagberg H, Hemmingsson A, Jung B. Magnetic resonance imaging for assessment of treatment effects in mediastinal Hodgkin's disease.Acta Radiol 1987; 28: 145–151.PubMedGoogle Scholar
  6. 6.
    Coakley AJ, Kettle A, Wells CP, O'Doherty MJ, Collins R. Technetium-99m-sestamibi: a new agent for parathyroid imaging.Nucl Med Commun 1989; 10: 791–794.PubMedGoogle Scholar
  7. 7.
    Burak Z, Argon M, Memis A, Erdem S, Balkan Z, Duman Y, Ustun EE, Erhan Y, Ozkilic H. Evaluation of palpable breast masses with99mTcm-MIBI: a comparative study with mammography and ultrasonography.Nucl Med Commun 1994; 15: 604–612.PubMedGoogle Scholar
  8. 8.
    Kao CH, Wang SJ, Liu TJ. The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses.Eur J Nucl Med 1994; 21: 432–436.PubMedGoogle Scholar
  9. 9.
    Piwnica-Worms D, Chiu ML, Budding M, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.Cancer Res 1993; 53: 977–984.PubMedGoogle Scholar
  10. 10.
    Ballinger JR, Hua HA, Berry BW, Firby P, Boxen I.99mTcm-sestamibi as an agent for imaging P-glycoprotein-mediated multi-drug resistance: in vitro and in vivo studies in a rat breast tumour cell line and its doxorubicin-resistant variant.Nucl Med Commun 1995; 16: 253–257.PubMedGoogle Scholar
  11. 11.
    Mansi L, Rambaldi PF, La Provitera A, Di Gregorio F, Procaccini E. Tc-99m tetrofosmin uptake in breast tumours.J Nucl Med 1995; 36: 83P.Google Scholar
  12. 12.
    Ballinger JR, Banneman J, Boxen I, Firby P, Berry BW, Moore MJ, Hartman NG. Accumulation of Tc-99m tetrofosmin in breast tumour cells in vitro: role of the multidrug-resistance P-glycoprotein.J Nucl Med 1995; 36: 202P.Google Scholar
  13. 13.
    Flamen P, Everaert H, Bossuyt A, Franken PR. Image analysis of Tc99-tetrofosmin in a one-day rest and dipyridamole stress myocardial SPECT imaging protocol. Intra-individual comparison with Tc99m-sestamibi.J Nucl Med 1995; 36: 24P.Google Scholar
  14. 14.
    Crankshaw CL, Marmion M, Burleigh BD, Deutsch E, Piwnica-Worms D. Non-reducible mixed ligand Tc(III)cations (Q-complexes) are recognized as transport substrates by the human multidrug resistance (MDR)P-glycoprotein.J Nucl Med 1995;36:130P.Google Scholar
  15. 15.
    Chiu ML, Kronange JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2 methoxyisobutyl isonitrile) technetium in cultured mouse fibroblasts.J Nucl Med 1990; 31: 1646–1653.PubMedGoogle Scholar
  16. 16.
    Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis-(alkylisonitril)-technetium-99m complexes.J Nucl Med 1990; 31: 1166–1167.PubMedGoogle Scholar
  17. 17.
    Delmon-moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis (2-methoxyisobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro.Cancer Res 1990; 50: 2198–2202.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Marion de Jong
    • 1
  • Bert F. Bernard
    • 2
  • Wout A. P. Breeman
    • 1
  • Geert Ensing
    • 3
  • Harry Benjamins
    • 3
  • Willem H. Bakker
    • 1
  • Theo J. Visser
    • 2
  • Eric P. Krenning
    • 1
  1. 1.Department of Nuclear MedicineUniversity Hospital Dijkzigt and Erasmus University Medical SchoolRotterdamThe Netherlands
  2. 2.Department of Internal Medicine IIIUniversity Hospital Dijkzigt and Erasmus University Medical SchoolRotterdamThe Netherlands
  3. 3.Mallinckrodt MedicalPettenThe Netherlands

Personalised recommendations